702
Participants
Start Date
July 1, 2024
Primary Completion Date
July 1, 2029
Study Completion Date
November 1, 2029
Huaier granule
Huaier granule, oral administration, 10g each time, 3 times a day. Continuous medication until disease progression, the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or until the researcher determines that the participants will no longer benefit, whichever occurs first. After disease progression, whether to continue the medication or not should be determined by the researcher and participant together. Participants will start taking Huaier granule within 1 to 3 weeks after surgery.
Oxaliplatin
Participants will receive intravenous infusion of 130 mg/m² oxaliplatin on the first day of treatment cycle.
Tegafur, Gimeracil and Oteracil Potassium
Participants will receive oral Tegafur, Gimeracil and Oteracil Potassium (40 mg/m², twice a day) for 2 weeks, followed by 1 week of rest.
Wuhan Union Hospital, Wuhan
The Affiliated Hospital of Qingdao University, Qingdao
LinkDoc Technology (Beijing) Co. Ltd.
INDUSTRY
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER